A randomized phase 3 trial of oral lenalidomide and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma. Final analysis of MM010 study

被引：0
|
作者：
Anagnostopoulos, A.
Dimopoulos, M. A.
Spencer, A.
Attal, M.
Prince, M.
Harousseau, J.-L.
Dmoszynska, A.
San Miguel, J.
Hellmann, A.
Facon, T.
Foa, R.
Lazzarino, M.
Masliak, Z.
Olesnyckyj, M.
Yu, Z.
Patin, J.
Zeldis, J. B.
Knight, R. D.
机构：
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：171 / 172
页数：2
相关论文
共 50 条
  • [1] Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 study (MM-010).
    Dimopoulos, MA
    Spencer, A
    Attal, M
    Prince, M
    Harousseau, JL
    Dmoszynska, A
    Yu, ZU
    Olesnyckyj, M
    Zeldis, J
    Knight, R
    [J]. BLOOD, 2005, 106 (11) : 6A - 7A
  • [2] OCEAN: A Phase 3, Randomized, Global Study of Melflufen and Dexamethasone Versus Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Refractory to Lenalidomide
    Sonneveld, Pieter
    Schjesvold, Fredrik
    Robak, Pawel
    Rossjey, Viktor
    Pour, Ludk
    Minarik, Jiri
    Delimpasi, Sosana
    Legic, Wojciech
    Salogub, Galina
    Harmenberg, Johan
    Byrne, Catriona
    Nordstrom, Eva
    Richardson, Paul G.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S25 - S25
  • [3] A Phase I Study of Bendamustine Combined with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma.
    Lentzsch, Suzanne
    O'Sullivan, Amy
    Lalo, Silvana
    Kruppa, Carrie
    Gardner, Diane
    Kennedy, Ryan C.
    Burt, Steve
    Mapara, Markus Y.
    Redner, Robert
    Roodman, David
    Volkin, Robert L.
    Zonder, Jeffrey
    [J]. BLOOD, 2009, 114 (22) : 736 - 736
  • [4] Roar: A Phase Ib Trial of Oral Azacitidine in Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma (MM) Patients Refractory to Prior Lenalidomide
    Kalff, Anna
    Reed, Kate
    Khong, Tiffany T.
    Mithraprabhu, Sridurga
    Ramachandran, Malarmathy
    Hall, Richard
    Bergin, Krystal
    Spencer, Andrew
    [J]. BLOOD, 2015, 126 (23)
  • [5] Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)
    Jakubowiak, Andrzej J.
    Richardson, Paul G.
    Zimmerman, Todd M.
    Alsina, Melissa
    Kaufman, Jonathan L.
    Kandarpa, Malathi
    Harvey, Colleen K.
    Colson, Kathleen
    Mitchell, Monica
    Hideshima, Teru
    Sportelli, Peter
    Gardner, Lesa
    Giusti, Kathy
    Anderson, Kenneth C.
    [J]. BLOOD, 2010, 116 (21) : 1264 - 1264
  • [6] A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
    Moreau, Philippe
    Richardson, Paul Gerard Guy
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raab, Marc
    Facon, Thierry
    Vij, Ravi
    Reece, Donna Ellen
    White, Darrell
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Rossi, Jean-Francois
    Tsao, Claire
    Parli, Teresa
    Kroog, Glenn Scott
    Singhal, Anil
    Lonial, Sagar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial
    Stewart, A. Keith
    Siegel, David
    Ludwig, Heinz
    Facon, Thierry
    Goldschmidt, Hartmut
    Jakubowiak, Andrzej J.
    Miguel, Jesus F. San
    Obreja, Mihaela
    Blaedel, Julie
    Dimopoulos, Meletios A.
    [J]. BLOOD, 2017, 130
  • [8] Pulsed oral dexamethasone in relapsed and refractory multiple myeloma.
    Smith, AG
    Crofts, SE
    WhatelySmith, C
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 310 - 310
  • [9] Phase lb study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.
    Laubach, Jacob
    Tuchman, Sascha Alexander
    Rosenblatt, Jacalyn
    Redd, Robert
    Colson, Kathleen
    Motta, Ashley
    Fitzpatrick, Kathleen
    Weller, Edie
    Richardson, Paul G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Touzeau, Cyrille
    Hungria, Vania T. M.
    Bhutani, Divaya
    Landgren, Ola
    Vieyra, Diego
    Guo, Yue
    Verona, Raluca
    Miao, Xin
    Qi, Mia
    Watkins, Latisha
    Shah, Priya
    Chastain, Katherine
    Qi, Ming
    Quach, Hang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345